110 related articles for article (PubMed ID: 30952631)
21. Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.
Huang D; Yang F; Wang Y; Guan X
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):148-156. PubMed ID: 28344099
[TBL] [Abstract][Full Text] [Related]
22. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
23. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A
Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472
[TBL] [Abstract][Full Text] [Related]
24. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
Jin Y; Hu W; Liu T; Rana U; Aguilera-Barrantes I; Kong A; Kumar SN; Wang B; Gao P; Wang X; Duan Y; Shi A; Song D; Yang M; Li S; Han B; Zhao G; Fan Z; Miao QR
Cancer Lett; 2018 Apr; 419():233-244. PubMed ID: 29373839
[TBL] [Abstract][Full Text] [Related]
25. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
26. Estrogen receptors in resistance to hormone therapy.
Herynk MH; Fuqua SA
Adv Exp Med Biol; 2007; 608():130-43. PubMed ID: 17993238
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptors as therapeutic targets in breast cancer.
Ariazi EA; Ariazi JL; Cordera F; Jordan VC
Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
[TBL] [Abstract][Full Text] [Related]
28. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
29. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
[TBL] [Abstract][Full Text] [Related]
30. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
31. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
32. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
33. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
[TBL] [Abstract][Full Text] [Related]
34. Roles for miRNAs in endocrine resistance in breast cancer.
Muluhngwi P; Klinge CM
Endocr Relat Cancer; 2015 Oct; 22(5):R279-300. PubMed ID: 26346768
[TBL] [Abstract][Full Text] [Related]
35. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
36. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
37. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Mittal R; Chaudhry N; Pathania S; Mukherjee TK
Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
[TBL] [Abstract][Full Text] [Related]
39. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
40. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S
Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]